AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
AALL1631 |
Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia |
New diagnosis |
NSW / QLD / WA |
External Registry ≫ |
Open |
19/04/2018 |
|
Treatment |
Phase 3 |
1 year to 21 years at diagnosis |
|
NCT03007147 |
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) |
AALL1731 |
B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma |
New diagnosis |
NSW / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
15/10/2019 |
|
Treatment |
Phase 3 |
1 year to 31 Years |
|
NCT03914625 |
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy |
AALL1732 |
B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Central Nervous System Leukemia
Mixed Phenotype Acute Leukemia
Testicular Leukemia |
New Diagnosis |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
28/10/2019 |
|
Treatment |
Phase 3 |
1 Year to 24 Years |
|
NCT03959085 |
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome |
AAML1531 |
Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm |
New diagnosis |
NSW / VIC / WA / NZ |
External Registry ≫ |
Open |
03/11/2015 |
|
Treatment |
Phase 3 |
90 days to 4 years |
|
NCT02521493 |
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) |
AAML18P1 |
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive |
On treatment |
VIC / WA |
External Registry ≫ |
Open |
15/07/2019 |
|
Treatment |
Phase 2 |
up to 25 years |
|
NCT03817398 |
ACNS1422: A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients |
ACNS1422 |
Medulloblastoma |
New diagnosis |
NSW / WA / SA |
External Registry ≫ |
Open |
|
|
Treatment |
Phase 2 |
3 years to 22 years at the time of enrollment |
|
NCT02724579 |
ACT001-AU-002: A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors |
ACT001-AU-002 |
Advanced brain tumour
Advanced solid tumour
|
Relapse/refractory |
NSW / WA |
External Registry ≫ |
Open |
18/09/2019 |
|
Treatment |
Phase 1 |
1 Year to 21 Years |
ACTRN12618001934235 |
|
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
AGCT1531 |
Germ Cell Tumour |
New diagnosis |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
08/05/2017 |
|
Treatment |
Phase 3 |
Various depending on risk group & consult protocol |
|
NCT03067181 |
ALLELE: Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy |
ALLELE (ATA129-EBV-302) |
EBV post transplant |
Refractory |
NSW / VIC / WA |
External Registry ≫ |
Open |
29/12/2017 |
|
Treatment |
Phase 3 |
no limits |
|
NCT03394365 |
ALTE03N1: Key Adverse Events After Childhood Cancer |
ALTE03N1 |
Childhood Malignant Neoplasm |
Previously treated |
QLD / WA / SA |
External Registry ≫ |
Open |
24/03/2004 |
|
Observational |
Not applicable |
up to 21 Years |
|
NCT00082745 |
ALTE07C1: Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer |
ALTE07C1 |
All Tumour Types
|
New diagnosis
Relapse/refractory |
QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
15/09/2008 |
|
Psycho-social |
Not applicable |
3 Years to 21 Years |
|
NCT00772200 |
ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy |
ALTE11C2 |
Hodgkin Lymphoma in Remission
Leukemia in Remission
Lymphoblastic Lymphoma
Osteosarcoma
Recurrent Leukemia
Recurrent Lymphoma
Recurrent Malignant Neoplasm |
Previously treated |
WA |
External Registry ≫ |
Open |
05/08/2013 |
|
Late Effects |
Not applicable |
no limits |
|
NCT01790152 |
ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study |
ALTE15N2 |
Recurrent Neuroblastoma |
Relapse/refractory |
WA / NZ |
External Registry ≫ |
Open |
05/06/2017 |
|
Late Effects |
Not applicable |
5 Years to 50 Years |
|
NCT03057626 |
ANBL1821: A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma |
ANBL1821 |
Solid tumours (Neuroblastoma) |
Relapse/refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
28/05/2019 |
|
Treatment |
Phase 2 |
1 Year and older |
|
NCT03794349 |
ANZUP 1302: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
ANZUP 1302 |
Germ Cell Tumour |
New diagnosis |
QLD / NZ |
External Registry ≫ |
Open |
01/02/2014 |
|
Treatment |
Phase 3 |
11 Years to 45 Years |
|
NCT02582697 |
APEC14B1: Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study |
APEC14B1 |
All Paediatric Cancer Types |
|
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
26/10/2015 |
|
Registry |
Not applicable |
up to 25 years |
|
NCT02402244 |
AREN03B2: Renal Tumors Classification Biology and Banking Study |
AREN03B2 |
Renal tumours |
Newly diagnosed |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
27/06/2007 |
|
Observational |
Not applicable |
up to 29 Years |
|
NCT00898365 |
AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
AREN1921 |
Anaplastic Kidney Wilms Tumor
Recurrent Kidney Wilms Tumor
Stage II Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor |
New Diagnosis
Relapse |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
18/09/2020 |
|
Treatment |
Phase 2 |
up to 30 Years |
|
NCT04322318 |
ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors |
ARST1921 |
Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis |
New Diagnosis
Relapse |
WA |
External Registry ≫ |
Open |
21/09/2020 |
|
Treatment |
Phase 2 |
12 Months to 18 Years |
|
NCT04195399 |
ASSET: Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia |
ASSET |
Acute Lymphoblastic Leukaemia (ALL) |
Previously treated |
NSW / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
20/08/2015 |
|
Registry |
Not applicable |
up to 18 years |
|
|
Developing genetically modified TCells for the treatment of paediatric solid tumours |
CARTpaedST |
Solid tumours |
New diagnosis |
NSW |
|
Open |
08/04/2018 |
|
Treatment |
Phase 1 |
up to 18 years |
|
|
CCTL019A2205B: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy |
CCTL019A2205B |
Patients who have received CAR-T cell therapy |
Previously treated |
VIC |
External Registry ≫ |
Open |
02/11/2015 |
|
Observational |
Not applicable |
Child, Adult, Older Adult |
|
NCT02445222 |
CFZ2008: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia |
CFZ2008 / 20140106 |
Acute Lymphoblastic Leukaemia (ALL) |
Relapse/refractory |
NSW / QLD / VIC / WA |
External Registry ≫ |
Open |
10/09/2015 |
|
Treatment |
Phase 1/2 |
1 Month to 21 Years |
|
NCT02303821 |
CONNECT1903: A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion |
CONNECT1903 |
High Grade Glioma (HGG)
Diffuse Intrinsic Pontine Glioma (DIPG) |
New diagnosis |
NSW / QLD / WA |
External Registry ≫ |
Open |
08/04/2021 |
|
Treatment |
Pilot |
up to 21 years |
|
NCT04655404 |
FIREFLY: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma |
DAY101-001 (FIREFLY) |
Low-grade Glioma |
Relapse/refractory |
NSW / QLD / VIC / WA / SA |
External Registry ≫ |
Open |
17/03/2021 |
|
Treatment |
Phase 2 |
6 Months to 25 Years |
|
NCT04775485 |
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue |
HeadStart4 |
Medulloblastoma
Central Nervous System Embryonal Tumors |
Newly diagnosed |
NZ |
External Registry ≫ |
Open |
01/09/2015 |
|
Treatment |
Phase 4 |
up to 10 Years |
|
NCT02875314 |
HoTRODS: Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies |
HoTRODS |
Diffuse Pontine Glioma
Diffuse Midline Glioma
High grade glioma |
New Diagnosis
Relapse |
NSW / WA |
External Registry ≫ |
Open |
17/07/2012 |
|
Observational |
Not applicable |
no limits |
ACTRN12612001183875 |
|
iMATRIX: A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available |
iMATRIX (GO42286) |
ALK Fusion-positive Solid or CNS Tumors |
Relapse/refractory |
NSW / VIC |
External Registry ≫ |
Open |
26/07/2021 |
|
Treatment |
Phase 1/2 |
up to 17 Years |
|
NCT04774718 |
INFORM2: Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies |
INFORM2 NivEnt |
CNS Tumour
Solid Tumour |
Recurrent/ refractory
|
NSW / VIC / WA |
External Registry ≫ |
Open |
26/07/2019 |
|
Treatment |
Phase 1/2 |
6 Years to 21 Years |
|
NCT03838042 |
LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis |
LCH-IV |
Langerhans Cell Histiocytosis |
New diagnosis |
NSW / QLD / VIC / WA / NZ / TAS |
External Registry ≫ |
Open |
14/04/2014 |
|
Treatment |
Phase 3 |
up to 18 years |
|
NCT02205762 |
LOXO-RET-18036: A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours |
LOXO-RET-18036 |
Medullary Thyroid Cancer
Infantile Myofibromatosis
Infantile Fibrosarcoma
Papillary Thyroid Cancer
Soft Tissue Sarcoma |
Relapse/ refractory |
NSW / VIC |
External Registry ≫ |
Open |
01/07/2019 |
|
Treatment |
Phase 1/2 |
6 months to 21 years |
|
NCT03899792 |
LOXO-TRK-15003: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors |
LOXO-TRK-15003 |
Solid Tumors Harboring NTRK Fusion |
New diagnosis
Relapse/ refractory |
NSW / VIC / WA |
External Registry ≫ |
Closed to Recruitment, Open |
11/09/2017 |
|
Treatment |
Phase 1/2 |
up to 21 years |
|
NCT02637687 |
NB SCI Registry: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI) |
NB SCI Registry |
Neuroblastic Tumors |
|
NSW / QLD / VIC / WA / SA / TAS |
External Registry ≫ |
Open |
01/04/2015 |
|
Registry |
Not applicable |
up to 18 Years |
|
NCT02559804 |
LGG Avastin: A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma |
OZM-063 (LGG Avastin) |
Low Grade Glioma |
New diagnosis
Relapse/ refractory |
NSW / QLD / VIC / WA / SA |
External Registry ≫ |
Open |
29/05/2018 |
|
Treatment |
Phase 2 |
6 months to 18 years old |
|
NCT02840409 |
P3505: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients |
P3505 |
Haematological diseases |
New Diagnosis
Relapse/Refractory |
QLD / VIC |
External Registry ≫ |
Open |
17/06/2020 |
|
Supportive Care |
Phase 1 |
3 months to 18 years |
ACTRN12620000141943 |
|
AALL1922: A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation |
Ponatinib-1501 /AALL1922 |
Leukaemia (ALL) |
Relapse/ refractory |
QLD / VIC / WA |
External Registry ≫ |
Open |
21/02/2021 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Years |
|
NCT04501614 |
PRISM: PRecISion Medicine for Children with Cancer |
PRISM |
All Paediatric Cancer Types |
New Diagnosis
Relapse/ Refractory |
NSW / VIC / WA |
External Registry ≫ |
Open |
05/09/2017 |
|
Biology |
Biology |
up to 21 years |
|
NCT03336931 |
R3ACT Fungal: A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation |
R3ACT Fungal |
Invasive Fungal Disease |
Newly diagnosed
Relapsed/Refractory |
NSW |
External Registry ≫ |
Open |
19/08/2019 |
|
Treatment |
Phase 1 |
1 Years to 80 Years |
ACTRN12618001540202 |
|
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma |
ReRAD |
Recurrent or Progressive Diffuse Intrinsic Pontine Glioma |
Relapsed/ refractory |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
15/04/2017 |
|
Treatment |
Phase 2 |
up to 17 years |
|
NCT03126266 |
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma |
RG_13-277 (rEECur) |
Ewings sarcoma |
Relapse/ refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
03/04/2018 |
|
Treatment |
Phase 2/3 |
4 years to 50 years |
ACTRN12618001825246 |
|
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma |
RG_17-427 (FaR-RMS) |
Rhabdomyosarcoma |
Relapsed/ refractory |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
17/09/2020 |
|
Treatment |
Phase 1 |
no limits |
|
NCT04625907 |
T2017-002: A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) |
T2017-002 |
Acute Lymphoblastic Leukaemia (ALL) |
Relapsed/ refractory |
NSW / VIC |
External Registry ≫ |
Open |
12/02/2019 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Years |
|
NCT03817320 |
TiNT: A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas |
TiNT |
Solid tumours |
Relapsed/ refractory |
NSW / VIC / WA / SA / NZ / TAS |
External Registry ≫ |
Open |
01/03/2021 |
|
Treatment |
Phase 2 |
3 Months to 25 Years |
ACTRN12620001229965 |
|
TOTAL 17: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
TOTAL 17 |
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma |
Newly diagnosed |
VIC |
External Registry ≫ |
Open |
01/12/2021 |
|
Treatment |
Phase 2/3 |
1 Year to 18 Years |
|
NCT03117751 |
TPX-0005-07: A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations |
TPX-0005-07 |
Solid tumours |
Relapsed/ refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
20/03/2020 |
|
Treatment |
Phase 1/2 |
up to 25 years |
|
NCT04094610 |
EFC16295: A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A |
EFC16295 |
Hemophilia A |
Recurrent/ refractory |
QLD |
External Registry ≫ |
Open |
19/02/2021 |
|
Treatment |
Phase 3 |
up to 12 years |
|
NCT04759131 |
ACNS2021: A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor |
ACNS2021 |
Central Nervous System Nongerminomatous Germ Cell Tumor
Choriocarcinoma
Embryonal Carcinoma
Immature Teratoma
Malignant Teratoma
Mixed Germ Cell Tumor
Pineal Region Germ Cell Tumor
Pineal Region Immature Teratoma
Pineal Region Yolk Sac Tumor
Suprasellar Germ Cell Tumor |
Newly diagnosed |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
04/06/2021 |
|
Treatment |
Phase 2 |
3 Years to 30 Years |
|
NCT04684368 |
DIPG: International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository |
DIPG |
Diffuse Intrinsic Pontine Glioma (DIPG)
Diffuse Midline Glioma, H3 K27M-Mutant
Diffuse Midline Glioma |
|
NSW / QLD / WA / NZ |
External Registry ≫ |
Open |
30/06/2012 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
NCT03101813 |
PPB DICER: International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions |
PPB DICER |
Pleuropulmonary Blastoma
Wilms Tumor
Pineoblastoma
Neuroblastoma
Embryonal Rhabdomyosarcoma |
|
NSW / WA |
External Registry ≫ |
Open |
06/12/2015 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
NCT03382158 |
Bu4Day-PK-2016: Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study |
Bu4Day-PK-2016 |
Haematopoietic Stem Cell Transplant |
Newly diagnosed
Relapsed/refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
29/05/2017 |
|
Observational |
Pilot |
up to 18 years |
ACTRN12617000227392 |
|
ACOR: Australian Cardio-Oncology Registry |
ACOR |
All paediatric cancer types |
Newly diagnosed |
NSW / VIC / WA / SA / TAS |
|
Open |
01/09/2018 |
|
Registry |
Not applicable |
up t 35 Years |
|
|
PREDICT: Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients |
PREDICT |
Neoplastic Syndromes, Hereditary
Cancer
Genetic Predisposition to Disease |
Newly diagnosed |
NSW |
External Registry ≫ |
Open |
08/03/2021 |
|
Observational |
Not applicable |
up to 21 years |
|
NCT04903782 |
ALL Registry: Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research |
Acute Leukaemia Registry |
Leukaemia |
|
NSW / QLD / VIC / WA / TAS |
|
Open |
01/04/2019 |
|
Registry |
Not applicable |
Child, Adult, Older Adult |
|
|
BLU-285-3101: A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling |
BLU-285-3101 |
Solid tumours
CNS Tumours |
Relapse/refractory
|
NSW / VIC |
External Registry ≫ |
Open |
14/10/2022 |
|
Treatment |
Phase 1/2 |
2 Years to 17 Years |
|
NCT04773782 |
ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
ANHL1931 |
Primary Mediastinal Large B-Cell Lymphoma |
Newly Diagnosed |
NSW / QLD / VIC / WA |
External Registry ≫ |
Open |
07/06/2021 |
|
Treatment |
Phase 3 |
2 Years and older |
|
NCT04759586 |
ARST2031: A Randomized Phase 3 Trial of Vinorelbine Dactinomycin and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) |
ARST2031 |
Rhabdomyosarcoma |
Newly diagnosed |
NSW / VIC / WA |
External Registry ≫ |
Open |
12/09/2023 |
|
Treatment |
Phase 3 |
up to 50 Years |
|
NCT04994132 |
MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients |
MetMED |
Medulloblastoma |
Previously treated |
NSW / VIC / WA |
External Registry ≫ |
Open |
28/09/2022 |
|
Treatment |
Phase 3 |
7 years to 17 years |
ACTRN12622000045718 |
|
M20-429: A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
M20-429 |
Non-Hodgkin Lymphoma |
Relapsed/refractory |
NSW / VIC / WA |
External Registry ≫ |
Open |
29/09/2022 |
|
Treatment |
Phase 1/2 |
1 Year to 21 Year5 |
|
NCT05206357 |
PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression |
PNOC022 |
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma |
Newly diagnosed
Relapsed/Refractory |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
18/08/2022 |
|
Treatment |
Phase 1/2 |
2 Years to 39 Years |
|
NCT05009992 |
CA224-069: A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
CA224-069 |
Non-Hodgkin Lymphoma |
Relapsed/Refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
01/11/2022 |
|
Treatment |
Phase 1/2 |
up to 30 Years |
|
NCT05255601 |
CONNECT2108: Phase 2 Study of the MEK inhibitor MEKTOVI® (binimetinib) for the treatment of Pediatric Adamantinomatous Craniopharyngioma |
CONNECT2108 |
Adamantinomatous Craniopharyngioma |
Relapsed/refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
08/05/2023 |
|
Treatment |
Phase 2 |
1 Year to 25 Years |
|
NCT05286788 |
CO43810: A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma |
CO43810 |
Mature B-Cell Non-Hodgkin Lymphoma |
Relapsed/refractory |
QLD / WA |
External Registry ≫ |
Open |
16/11/2022 |
|
Treatment |
Phase 1/2 |
6 Months to 30 Years |
|
NCT05533775 |
D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours |
D0816C00025 |
Solid Tumours |
Relapsed/refractory |
NSW / WA |
External Registry ≫ |
Open |
01/11/2022 |
|
Treatment |
Phase 1 |
0 Years to 18 Years |
|
NCT04236414 |
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Pediatric Adamantinomatous Craniopharyngioma |
CONNECT1905 |
Adamantinomatous Craniopharyngioma |
Relapsed/refractory |
NSW / QLD / WA |
External Registry ≫ |
Open |
19/12/2022 |
|
Treatment |
Phase 2 |
1 Year to 25 Years |
|
NCT05233397 |
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
ACNS1821 |
Anaplastic Astrocytoma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
Glioblastoma, Not Otherwise Specified
Malignant Glioma |
Newly diagnosed |
NSW / QLD / VIC / NZ |
External Registry ≫ |
Open |
05/05/2022 |
|
Treatment |
Phase 1/2 |
12 Months to 21 Years |
|
NCT05099003 |
APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations |
APEC1621F |
All paediatric cancer types |
Relapsed/refractory |
WA |
External Registry ≫ |
Open |
17/04/2018 |
|
Treatment |
Phase 2 |
12 Months to 21 Years |
|
NCT03213652 |
ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma |
ARET2121 |
Bilateral Retinoblastoma
Childhood Intraocular Retinoblastoma
Group D Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma |
Newly diagnosed |
WA |
External Registry ≫ |
Open |
|
|
Treatment |
Phase 2 |
up to 18 Years |
|
NCT05504291 |
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma |
AOST2031 |
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma |
Newly diagnosed |
NSW / VIC / WA / NZ |
External Registry ≫ |
Open |
13/01/2023 |
|
Treatment |
Phase 3 |
up to 50 Years |
|
NCT05235165 |
ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma |
ARST2032 |
Embryonal Rhabdomyosarcoma
Fusion-Negative Alveolar Rhabdomyosarcoma
Spindle Cell/Sclerosing Rhabdomyosarcoma |
Newly diagnosed |
NSW / WA / NZ |
External Registry ≫ |
Open |
09/12/2022 |
|
Treatment |
Phase 3 |
up to 21 years |
|
NCT05304585 |
ASCT2031: A Multi-Center Phase 3 Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children Adolescents and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS) |
ASCT2031 |
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome |
Newly diagnosed |
NSW |
External Registry ≫ |
Open |
12/12/2023 |
|
Treatment |
Phase 3 |
6 Months to 22 Years |
|
NCT05457556 |
Firefly-2: A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy |
Firefly-2 |
Low-Grade Glioma |
Newly diagnosed |
NSW / QLD / VIC / WA / SA / NZ |
External Registry ≫ |
Open |
19/05/2023 |
|
Treatment |
Phase 3 |
up to 25 Years |
|
NCT05566795 |
APAL2020D: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML |
APAL2020D |
Acute myeloid leukemia |
Relapsed/refractory |
QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
01/10/2022 |
|
Treatment |
Phase 3 |
29 Days to 21 Years |
|
NCT05183035 |
TAK-620-2004: A Phase 3 Open-label Single-arm Repeated-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
TAK-620-2004 |
Cytomegalovirus (CMV) |
Previously treated |
NSW / QLD / WA |
External Registry ≫ |
Open |
29/05/2024 |
|
Treatment |
Phase 3 |
up to 17 Years |
|
NCT05319353 |
APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias |
APAL2020SC |
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy
Juvenile Myelomonocytic Leukemia
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome Post Cytotoxic Therapy
Myeloid Leukemia Associated With Down Syndrome |
Relapsed/refractory |
NSW / QLD / VIC / WA / NZ |
External Registry ≫ |
Open |
30/11/2021 |
|
Observational |
Not applicable |
up to 22 Years |
|
NCT04726241 |
ZERO2: Precision Medicine for Every Child With Cancer |
ZERO2 |
All paediatric cancer types
|
Newly diagnosed
Relapsed/Refractory |
NSW / QLD / VIC / WA / SA / NZ / TAS |
External Registry ≫ |
Open |
16/12/2022 |
|
Observational |
Not applicable |
0 Years to 25 Years |
|
NCT05504772 |
LTS16294: A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A |
LTS16294 |
Hemophilia A
|
Previously treated |
NSW / QLD / WA |
External Registry ≫ |
Open |
23/02/2022 |
|
Treatment |
Phase 3 |
Child, Adult, Older Adult |
|
NCT04644575 |
HR NBL2: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
HR NBL2 |
Neuroblastoma |
Newly diagnosed |
NSW / VIC |
External Registry ≫ |
Open |
31/03/2023 |
|
Treatment |
Phase 3 |
up to 20 years |
|
NCT04221035 |
CAMPFIRE: A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma |
CAMPFIRE- J1S-MC-JP04 |
Ewing Sarcoma
Neoplasm Metastasis |
Relapsed/refractory |
NSW / VIC |
External Registry ≫ |
Open |
10/09/2022 |
|
Treatment |
Phase 2 |
1 Year to 39 Years |
|
NCT05440786 |
PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
PEPN2121 |
Atypical Teratoid/Rhabdoid Tumor
Epithelioid Sarcoma
Kidney Medullary Carcinoma
Malignant Solid Neoplasm
Poorly Differentiated Chordoma
Recurrent Atypical Teratoid/Rhabdoid Tumor
Recurrent Chordoma
Recurrent Epithelioid Sarcoma
Recurrent Kidney Medullary Carcinoma
Recurrent Malignant Solid Neoplasm
Recurrent Rhabdoid Tumor
Refractory Atypical Teratoid/Rhabdoid Tumor
Refractory Chordoma
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Rhabdoid Tumor |
Newly diagnosed
Relapsed/Refractory |
NSW / QLD |
External Registry ≫ |
Open |
16/08/2024 |
|
Treatment |
Phase 1/2 |
12 Months and older |
|
NCT05286801 |
PEPN22P1: A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods |
PEPN22P1 |
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm |
Newly diagnosed
Relapsed/Refractory |
QLD |
External Registry ≫ |
Open |
22/06/2023 |
|
Treatment |
Pilot |
up to 12 Years |
|
NCT05359237 |
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
AOST2032 |
High Grade Osteosarcoma
Localized Osteosarcoma
Metastatic Osteosarcoma
Secondary Osteosarcoma |
Newly diagnosed |
NSW / VIC / NZ |
External Registry ≫ |
Open |
|
|
Treatment |
Phase 2/3 |
up to 40 Years |
|
NCT05691478 |
T2020-006: A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies |
T2020-006 |
Acute lymphoblastic leukemia
Acute myeloid leukemia
Myelodysplastic syndrome
Mixed phenotype acute leukemia
Acute undifferentiated leukemia
Blastic plasmacytoid dendritic cell neoplasm
Hodgkin lymphoma
Non-Hodgkin lymphoma |
Relapsed/refractory |
NSW / VIC |
External Registry ≫ |
Open |
11/11/2022 |
|
Treatment |
Phase 1 |
1 Year to 21 Years |
|
NCT05476770 |
The CLOCK Trial: Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial) |
The CLOCK Trial |
All paediatric cancers
Central vascular access device (CVAD) related adverse events |
|
NSW / QLD / VIC |
External Registry ≫ |
Open |
10/07/2023 |
|
Observational |
Not applicable |
0 Years to 18 Years |
ACTRN12622000499785 |
|
Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia |
Interfant21 |
B- precursor acute lymphoblastic leukemia (ALL)
B- cell mixed phenotype acute leukemia (MPAL) |
Newly diagnosed |
NSW / QLD / VIC / WA / SA |
External Registry ≫ |
Open |
30/04/2024 |
|
Treatment |
Phase 3 |
up to 1 Year |
|
NCT05327894 |
ONC201-108: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind Placebo-Controlled Multicenter Study |
ONC201-108 |
H3 K27M-mutant diffuse glioma |
Newly diagnosed |
NSW / WA / TAS |
External Registry ≫ |
Open |
|
|
Treatment |
Phase 3 |
Child, Adult, Older Adult |
|
NCT05580562 |
DEFLEXIFOL (DART): Phase I/II Trial of Deflexifol for Refractory/Recurrent Paediatric Ependymoma |
DEFLEXIFOL (DART) |
Ependymoma |
Relapsed/refractory |
NSW / QLD / VIC / WA / SA |
External Registry ≫ |
Open |
28/08/2023 |
|
Treatment |
Phase 1/2 |
12 Months to 21 Years |
ACTRN12623000104651 |
|
AAML1831: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations |
AAML1831 |
Acute Myeloid Leukemia |
Newly diagnosed |
QLD |
External Registry ≫ |
Open |
21/07/2020 |
|
Treatment |
Phase 3 |
up to 21 Years |
|
NCT04293562 |
CBYL719P12201: A Two-stage Double-blind Randomized Placebo-controlled Study to Assess the Efficacy Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Associated Lymphatic Malformations With a PIK3CA Mutation. |
CBYL719P12201 |
Lymphatic Malformations |
Newly diagnosed
Relapsed/Refractory |
QLD |
External Registry ≫ |
Open |
24/11/2023 |
|
Treatment |
Phase 1/2 |
2 Years and older |
|
NCT05948943 /
|
P305: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients |
P305 |
Haematological diseases |
New Diagnosis
Relapse/Refractory
|
VIC |
External Registry ≫ |
Open |
17/06/2020 |
|
Supportive Care |
Phase 1 |
3 months to 18 years |
ACTRN12620000141943 |
|
CLEE011Q12101: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors |
CLEE011Q12101 |
Neuroblastoma
Medulloblastoma
High-grade glioma
Malignant rhabdoid tumor
Rhabdomyosarcoma
|
Relapse/refractory
|
NSW |
External Registry ≫ |
Open |
27/12/2022 |
|
Interventional |
Phase 1/2 |
12 months to 21 years |
|
NCT05429502 /
|
REGO-EWING: Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma |
REGO-EWING |
Multimetastatic Ewing Sarcoma |
Newly diagnosed |
QLD / VIC / WA |
External Registry ≫ |
Open |
27/03/2023 |
|
Treatment |
Phase 1 |
2 Years to 50 Years |
|
NCT05830084 |
INTER-EWING-1: INTERnational scientific program in clinical research to improve outcomes of newly diagnosed EWING sarcoma |
RG_21-151 (INTER-EWING-1) |
Ewing Sarcoma |
Newly Diagnosed |
VIC / WA / NZ |
External Registry ≫ |
Open |
21/06/2024 |
|
Treatment |
Phase 3 |
≥2 years |
ACTRN12624000532505 |
ISRCTN17938906 |
OPTIMISE: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer |
OPTIMISE |
Bone Cancers
Brain and other CNS Tumours
Germ Cell Tumours
Hodgkin Lymphoma
Kidney (Renal) Tumours
Leukaemia
Liver tumours
Neuroblastoma
Non-Hodgkin Lymphoma
Retinoblastoma
Soft Tissue Sarcomas
Other |
Relapsed/Recurrent |
NSW / QLD / VIC / WA |
External Registry ≫ |
Open |
01/03/2024 |
|
Treatment |
Phase 1/2 |
0 - 21 years |
NCT06208657 |
|
VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas |
VICTORY |
Brain and other Central Nervous System (CNS) Tumours
Low Grade Glioma |
Relapsed/Recurrent |
WA |
External Registry ≫ |
Open |
23/12/2024 |
|
Treatment |
Pilot |
Up to 25 Years |
|
NCT06381570 |